NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
top of page
MCT is a Myeloma Education Website to provide a seamless source of information for Myeloma community around the world.
NCT03710603 - A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy (Perseus)
N Engl J Med - Publication - January 25, 2024